Sign Out
Asthma: Symbicort Rapihaler is indicated in the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: patients not adequately controlled with inhaled corticosteroids and "as needed" inhaled short-acting β2 adrenoceptor agonists. or; patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.
Chronic Obstructive Pulmonary Disease (COPD): Symbicort Rapihaler is indicated in adults, aged 18 and older, for the symptomatic treatment of patients with COPD with FEV1 <70% predicted normal (post-bronchodilator) and an exacerbation history despite regular bronchodilator therapy.
